头孢匹胺在重症急性胰腺炎小鼠中血胰屏障通透性的实验观察

目的：研究头孢匹胺（CPM）在重症急性胰腺炎（SAP）小鼠血胰屏障的通透性，为头孢匹胺防治胰腺组织感染提供理论依据。方法以20%L-精氨酸2 g·kg-1体重腹腔注射方法复制SAP模型。正常对照组和SAP模型组小鼠均尾静脉注射头孢匹胺42.5 mg·kg-1，在规定时间点取样，用高效液相色谱法（HPLC）测定血浆和胰腺组织中药物的浓度。结果头孢匹胺在正常动物组和SAP模型组血浆和胰腺中的处置均符合一室模型。正常动物组CPM对血胰屏障平均穿透率（PR）可达（49.2±38.4）%，血浆和胰腺组织中的t1/2分别为1.42 h和1.14 h，AUC分别为122.73 mg·h·L-1和69.88 mg·h·kg-1。SAP模型组PR平均可达（56.±34.7）%，与正常动物组相比无显著性差异，胰腺组织中t1/2、C0及AUC0-∞与正常动物组相近。结论头孢匹胺在SAP小鼠胰腺中有良好的分布，值得向临床推荐用于预防和治疗胰腺感染。

Permeability of Cefpiramide through Blood-pancreatic Barrier in the Mice with Sever Acute Pancreatitis

Objective To investigate the permeability of cefpiramide （CPM） through blood-pancreatic barrier in the mice with sever acute pancreatitis（SAP）. Methods CPM （42.5 mg·kg-1 body weight） was intravenous injected to mice after abdominally injecting L-arginine to induce sever acute pancreatitis while normal saline injection as control. At the given time points, the serum and pancreatic samples were collected. The concentrations of CPM in the samples were measured by HPLC. Results The disposition of CPM in two groups fitted one compartment model. The average penetration ratios （PR） of the drug through the blood-pancreas barrier in normal control group was （49.2±38.4）%. The parameters in plasma were as follows：t1/2 1.42 h, C0 59.93 mg·L-1, AUC0-∞122.73 mg·h·L-1, and those in tissue were as follows： t1/2 1.14 h, C0 22.58 mg·kg-1, AUC0-∞69.88 mg·h·kg-1. In SAP group, there was no significant difference in average PR、t1/2、C0 and AUC0-∞of CPM in the tissue compared with the normal control group （P〈0.05）. Conclusion CPM was shown to have a fairly high distribution in the pancreas in the SAP mice. It is therefore proposed that CPM may be used clinically for the prevention and treatment of pancreatic infection.